<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The study concerns 131 patients with a history of <z:hpo ids='HP_0004850'>recurrent deep vein thrombosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The predisposing and triggering factors of <z:mp ids='MP_0005048'>thrombosis</z:mp> have been carefully recorded and a study of hemostasis parameters has been performed, including AT III determination, fibrinolytic activity before and after venous occlusion, plasminogen, alpha 2-antiplasmin and histidine-rich <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> determination </plain></SENT>
<SENT sid="2" pm="."><plain>A congenital AT III deficiency was detected in six patients (4.4%) </plain></SENT>
<SENT sid="3" pm="."><plain>The most frequent finding was a decrease in fibrinolytic activity after venous occlusion </plain></SENT>
<SENT sid="4" pm="."><plain>If one accounts for patients with a disease predisposing to <z:mp ids='MP_0005048'>thrombosis</z:mp>: <z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et's disease, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, <z:hpo ids='HP_0002036'>hiatus hernia</z:hpo>, Cockett's syndrome (14 patients), or a biological anomaly such as: deficiency in AT III, decrease in fibrinolytic activity. circulating <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>, increase in <z:chebi fb="23" ids="18059">lipids</z:chebi> or <z:chebi fb="3" ids="27226">uric acid</z:chebi>, decrease in plasminogen or increase in alpha 2-antiplasmin (57 patients), there are still 60 patients (45% of the cases) in whom thromboses remain unexplained </plain></SENT>
</text></document>